Evidence map›Paper›PMID 42329260›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026

Successful palliative hypofractionated radiotherapy with superficial hyperthermia for heavily pretreated cutaneous breast cancer lesions.

D M V de Vries-Huizing, A Holtmaat, M W Kolff, J Crezee

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

D M V de Vries-HuizingDepartment of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-1967-8148
A HoltmaatDepartment of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
M W KolffDepartment of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-8654-8645
J CrezeeDepartment of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. h.crezee@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-7474-0533

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypofractionated radiotherapy has been successfully shown to reduce pain and skin lesion bleeding. In previously irradiated areas, the effect of hypofractionated radiotherapy (weekly 4 Gy radiotherapy to a total dose of 20 Gy) can be enhanced by hyperthermia: increasing temperatures in target areas up to 43 °C. Superficial hyperthermia in combination with radiotherapy is a proven and widely applied treatment for recurrent breast cancer and malignant melanoma. Literature on the use of radiotherapy to cause hemostasis of the skin is available; however, the role of hyperthermia in combination with radiotherapy for this indication is not yet described. SHORT COMMUNICATION: We present a 72-year old woman with a history of breast cancer with painful and bleeding cutaneous metastases in the right upper arm and right breast which had a large impact on her quality of life. The metastases progressed under T‑deruxtecan treatment, and she was referred for re-irradiation to control the bleeding skin. Hyperthermia was added as a tumor-selective radiosensitizer to the radiotherapy fractions to enhance irradiation. The main treatment goal was to reduce bleeding and itching of the cutaneous lesions. The patient was treated once a week with hyperthermia immediately followed by 4 Gy radiotherapy fractions for 5 consecutive weeks. Bleeding was already decreased during the treatment series and the skin healed within 4 weeks after therapy.

conclusionTreatment with 5 × 4 Gy radiotherapy combined with hyperthermia sessions was a successful palliative therapy for bleeding cutaneous metastases. The treatment schedule was well-tolerated and the skin fully recovered within 1 month.

Indexed as

Quality of LifeRadiosensitizationRe-irradiationSkin metastasesSuperficial hyperthermia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.